avVaa: NeuroSkin decreases eczema redness by 59%, itching by 45%

By Elaine Rigoli

Tampa, Fla., July 10 - avVaa World Health Care Products, Inc. said its NeuroSkin trial demonstrating the efficacy of patented nanoparticle silicic acid on eczema patients suggested a 59% decrease in erythema (skin redness), a 45% reduction in itching, a 70% reduction in skin scaling and a 63% improvement in infiltration.

The company also released data from two other studies using nanoparticle silicon. The first trial, on children with eczema, and the second trial, on adults with psoriasis, showed similar results.

The percentage of patients experiencing greater than 50% reduction in symptoms was 85% and 71% in the two studies, respectively. The company said 90% reported an improvement in the quality of life index.

The company said that, unlike commonly prescribed treatments for eczema (including steroids, UV light, coal tar or chemotherapy), NeuroSkin does not require treatment breaks or limited use, since there are no known ill effects or toxicities.

NeuroSkin contains silicic acid, a silicon-containing molecule found to be safe for topical application.

avVaa is a Lumby, B.C.-based biotechnology company that specializes in therapeutic skin care products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.